Logo image of QTTB

Q32 BIO INC (QTTB) Stock Fundamental Analysis

USA - NASDAQ:QTTB - US7469641051 - Common Stock

2.8 USD
-0.17 (-5.72%)
Last: 10/27/2025, 4:47:10 PM
2.85 USD
+0.05 (+1.79%)
After Hours: 10/27/2025, 4:47:10 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to QTTB. QTTB was compared to 534 industry peers in the Biotechnology industry. QTTB may be in some trouble as it scores bad on both profitability and health. QTTB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year QTTB has reported negative net income.
In the past year QTTB has reported a negative cash flow from operations.
QTTB had negative earnings in each of the past 5 years.
In the past 5 years QTTB always reported negative operating cash flow.
QTTB Yearly Net Income VS EBIT VS OCF VS FCFQTTB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -75.58%, QTTB is not doing good in the industry: 65.92% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -75.58%
ROE N/A
ROIC N/A
ROA(3y)-62.55%
ROA(5y)-56.34%
ROE(3y)-332.65%
ROE(5y)-224.01%
ROIC(3y)N/A
ROIC(5y)N/A
QTTB Yearly ROA, ROE, ROICQTTB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for QTTB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
QTTB Yearly Profit, Operating, Gross MarginsQTTB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

3

2. Health

2.1 Basic Checks

QTTB does not have a ROIC to compare to the WACC, probably because it is not profitable.
QTTB has more shares outstanding than it did 1 year ago.
QTTB has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, QTTB has a worse debt to assets ratio.
QTTB Yearly Shares OutstandingQTTB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
QTTB Yearly Total Debt VS Total AssetsQTTB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

QTTB has an Altman-Z score of -5.91. This is a bad value and indicates that QTTB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of QTTB (-5.91) is worse than 64.79% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.91
ROIC/WACCN/A
WACC8.66%
QTTB Yearly LT Debt VS Equity VS FCFQTTB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 4.71 indicates that QTTB has no problem at all paying its short term obligations.
QTTB has a Current ratio (4.71) which is comparable to the rest of the industry.
A Quick Ratio of 4.71 indicates that QTTB has no problem at all paying its short term obligations.
The Quick ratio of QTTB (4.71) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.71
Quick Ratio 4.71
QTTB Yearly Current Assets VS Current LiabilitesQTTB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

QTTB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 86.42%, which is quite impressive.
QTTB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)86.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.07%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.30% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y82.51%
EPS Next 2Y32.85%
EPS Next 3Y19.3%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
QTTB Yearly Revenue VS EstimatesQTTB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 10M 20M 30M
QTTB Yearly EPS VS EstimatesQTTB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

QTTB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QTTB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QTTB Price Earnings VS Forward Price EarningsQTTB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QTTB Per share dataQTTB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3 -4 -5

4.3 Compensation for Growth

A more expensive valuation may be justified as QTTB's earnings are expected to grow with 19.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.85%
EPS Next 3Y19.3%

More info and screens

0

5. Dividend

5.1 Amount

QTTB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Q32 BIO INC

NASDAQ:QTTB (10/27/2025, 4:47:10 PM)

After market: 2.85 +0.05 (+1.79%)

2.8

-0.17 (-5.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-06 2025-11-06
Inst Owners51.06%
Inst Owner Change0%
Ins Owners0.59%
Ins Owner Change-1.55%
Market Cap34.16M
Revenue(TTM)N/A
Net Income(TTM)-59762000
Analysts80
Price Target10.2 (264.29%)
Short Float %5.08%
Short Ratio1.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.47%
Min EPS beat(2)24.69%
Max EPS beat(2)28.26%
EPS beat(4)2
Avg EPS beat(4)4.36%
Min EPS beat(4)-33.54%
Max EPS beat(4)28.26%
EPS beat(8)3
Avg EPS beat(8)-70.48%
EPS beat(12)5
Avg EPS beat(12)-48.8%
EPS beat(16)9
Avg EPS beat(16)-32.31%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)24.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.3
EYN/A
EPS(NY)-4.47
Fwd EYN/A
FCF(TTM)-5.35
FCFYN/A
OCF(TTM)-5.34
OCFYN/A
SpS0
BVpS-0.33
TBVpS-0.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -75.58%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.55%
ROA(5y)-56.34%
ROE(3y)-332.65%
ROE(5y)-224.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.71
Quick Ratio 4.71
Altman-Z -5.91
F-Score1
WACC8.66%
ROIC/WACCN/A
Cap/Depr(3y)51.62%
Cap/Depr(5y)46.08%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.07%
EPS Next Y82.51%
EPS Next 2Y32.85%
EPS Next 3Y19.3%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-133.59%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.2%
OCF growth 3YN/A
OCF growth 5YN/A

Q32 BIO INC / QTTB FAQ

Can you provide the ChartMill fundamental rating for Q32 BIO INC?

ChartMill assigns a fundamental rating of 1 / 10 to QTTB.


What is the valuation status of Q32 BIO INC (QTTB) stock?

ChartMill assigns a valuation rating of 0 / 10 to Q32 BIO INC (QTTB). This can be considered as Overvalued.


How profitable is Q32 BIO INC (QTTB) stock?

Q32 BIO INC (QTTB) has a profitability rating of 0 / 10.


What is the expected EPS growth for Q32 BIO INC (QTTB) stock?

The Earnings per Share (EPS) of Q32 BIO INC (QTTB) is expected to grow by 82.51% in the next year.